Literature DB >> 11953329

Cyclooxygenase inhibition: between the devil and the deep blue sea.

C J Hawkey1.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) account for more reports of drug related toxicity than any other class of drugs. Their most widely recognised adverse effects are on the gastrointestinal tract. They cause acute erosions and chronic ulcers that result in hospitalisation and death because of ulcer bleeding and perforation. Between them, aspirin and non-aspirin NSAIDs may account for more than half of all episodes of ulcer bleeding and perforation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11953329      PMCID: PMC1867681          DOI: 10.1136/gut.50.suppl_3.iii25

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  61 in total

Review 1.  Nonsteroidal anti-inflammatory drug gastropathy.

Authors:  C J Hawkey
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

2.  Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease.

Authors:  F Degner; R Sigmund; H Zeidler
Journal:  Clin Ther       Date:  2000-04       Impact factor: 3.393

3.  Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.

Authors:  N J Wight; K Gottesdiener; N M Garlick; C T Atherton; S Novak; B J Gertz; N A Calder; J Cote; P Wong; A Dallob; C J Hawkey
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

4.  Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.

Authors:  A Whelton; J G Fort; J A Puma; D Normandin; A E Bello; K M Verburg
Journal:  Am J Ther       Date:  2001 Mar-Apr       Impact factor: 2.688

5.  A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.

Authors:  L Laine; S Harper; T Simon; R Bath; J Johanson; H Schwartz; S Stern; H Quan; J Bolognese
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

6.  The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam.

Authors:  S S Jick
Journal:  Pharmacotherapy       Date:  2000-07       Impact factor: 4.705

7.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

8.  A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.

Authors:  R H Hunt; B Bowen; E R Mortensen; T J Simon; C James; A Cagliola; H Quan; J A Bolognese
Journal:  Am J Med       Date:  2000-08-15       Impact factor: 4.965

9.  NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2.

Authors:  J L Wallace; W McKnight; B K Reuter; N Vergnolle
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

10.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

View more
  12 in total

Review 1.  Antiplatelet agents in clinical practice and their haemorrhagic risk.

Authors:  Paolo Gresele
Journal:  Blood Transfus       Date:  2013-05-09       Impact factor: 3.443

Review 2.  COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Authors:  Michael Riedel; Martin Strassnig; Markus J Schwarz; Norbert Müller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Single dose dipyrone for acute postoperative pain.

Authors:  Jayne Edwards; Fuensanta Meseguer; Clara Faura; R Andrew Moore; Henry J McQuay; Sheena Derry
Journal:  Cochrane Database Syst Rev       Date:  2010-09-08

Review 4.  Single-dose intravenous ibuprofen for acute postoperative pain in adults.

Authors:  McKenzie C Ferguson; Roman Schumann; Sean Gallagher; Ewan D McNicol
Journal:  Cochrane Database Syst Rev       Date:  2021-09-09

5.  Analgesic Efficacy of Firocoxib, a Selective Inhibitor of Cyclooxygenase 2, in a Mouse Model of Incisional Pain.

Authors:  Balagangadharreddy Reddyjarugu; Todd Pavek; Teresa Southard; Jason Barry; Bhupinder Singh
Journal:  J Am Assoc Lab Anim Sci       Date:  2015-07       Impact factor: 1.232

Review 6.  Single dose dipyrone (metamizole) for acute postoperative pain in adults.

Authors:  Leslie Hearn; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2016-04-20

7.  Peroxisome proliferator-activated receptor gamma activation counters the detrimental effect of Helicobacter pylori lipopolysaccharide on gastric mucin synthesis.

Authors:  B L Slomiany; A Slomiany
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

8.  Single-dose intravenous ketorolac for acute postoperative pain in adults.

Authors:  Ewan D McNicol; McKenzie C Ferguson; Roman Schumann
Journal:  Cochrane Database Syst Rev       Date:  2021-05-17

Review 9.  Single-dose intravenous diclofenac for acute postoperative pain in adults.

Authors:  Ewan D McNicol; McKenzie C Ferguson; Roman Schumann
Journal:  Cochrane Database Syst Rev       Date:  2018-08-28

10.  The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein.

Authors:  Kelitha Maxis; Aline Delalandre; Johanne Martel-Pelletier; Jean-Pierre Pelletier; Nicolas Duval; Daniel Lajeunesse
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.